KCL Capital’s Adaptive Biotechnologies ADPT Stock Holding History

KCL Capital’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-8,500	Closed	-$411K	–	33
2019 Q2	$411K	Buy	+8,500	New	+$377K	0.04%	33

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

SIG

Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

KCL Capital's ADPT Position: Q3 2019 in Review

KCL Capital sold out of Adaptive Biotechnologies (ADPT) in Q3 2019, closing a stake of 8,500 shares — an estimated $411K sold.

KCL Capital first reported a position in ADPT in Q2 2019 and held it in 1 quarter. The position peaked at $411K in Q2 2019. 117 funds tracked by Wall St. Rank hold ADPT as of Q3 2019.

KCL Capital reported no remaining Adaptive Biotechnologies position as of Q3 2019 after selling out during the quarter.
KCL Capital sold 8,500 Adaptive Biotechnologies shares in Q3 2019, an estimated $411K.
KCL Capital first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 1 quarter.
KCL Capital's Adaptive Biotechnologies position peaked at $411K in Q2 2019.
117 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2019.

Based on KCL Capital's 13F filing for Q3 2019, filed 14 Nov 2019.